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TRANSPLANTATION
Treatment of acute graft-versus-host disease with prednisolone: significant
survival advantage for day5 responders and no advantage for nonresponders
receiving anti–thymocyte globulin
Maria Teresa Van Lint, Giuseppe Milone, Salvatore Leotta, Cornelio Uderzo, Rosanna Scime`, Sandro Dallorso, Anna Locasciulli,
Stefano Guidi, Nicola Mordini, Simona Sica, Laura Cudillo, Franca Fagioli, Carmine Selleri, Barbara Bruno, William Arcese, and
Andrea Bacigalupo, for the Gruppo Italiano Trapianto Midollo Osseo (GITMO)
Newly diagnosed patients with acute graft-
versus-host disease (GvHD, grades I-IV;
n  211) were given 6-methylprednisolone
(6MPred) 2 mg/kg per day for 5 consecu-
tive days; 150 patients (71%) tapered
6MPred on day 5 and were considered
responders; 61 patients (29%) could not
taper their steroid dose and were consid-
ered nonresponders. The cumulative inci-
dence of transplant-related mortality
(TRM) for responders and nonresponders
is, respectively, 27% and 49% (P  .009),
and the 5-year survival is 53% and 35%
(P  .007). Nonresponders on day 5
(n  61) were randomized to receive
6MPred 5 mg/kg per day for 10 days alone
(n  34) or in combination with rabbit
anti–thymocyte globulin (ATG, 6.25 mg/kg
in 10 days; n  27). The 2 groups were
balanced for clinical and GvHD character-
istics. One month after randomization,
26% had a complete response; 23%, a
partial response; 33%, stable GvHD; 10%,
worsened; and 8%, died. There was no
significant difference in response, TRM,
and survival between the non-ATG and
ATG group. In conclusion, 5 days of pred-
nisolone as first-line therapy of acute
GvHD identifies patients with different
risk of TRM, and second-line therapy with
a combination of 6MPredATG does not
improve patient outcome, compared with
6MPred alone. (Blood. 2006;107:4177-4181)
© 2006 by The American Society of Hematology
Introduction
Acute graft-versus-host disease (GvHD) remains a major problem
following allogeneic hematopoietic stem cell transplantation (HSCT)
and a significant cause of death, especially in patients with
advanced disease who have received an allograft from an unrelated
donor.1 Treatment of acute GvHD is difficult because steroids and
other immunosuppressants increase the likelihood of lethal infec-
tions, whether or not GvHD has been controlled.2 In one large study
on 453 patients given prednisone 60 mg/m2 for 2 weeks as first-line
therapy, followed by an 8-week taper, an overall improvement was
observed in 55% of the patients, with durable ( 28 days) complete
responses in 35%.3 The probability of survival at 1 year after
initiation of therapy was 53%; favorable predictors of survival
were younger age of patients, HLA-identical sibling donors, and
GvHD prophylaxis other than ex vivo T-cell depletion.3 Whether a
higher dose of corticosteroids would be more effective was
assessed in a prospective trial of the Italian Cooperative Transplant
Group (GITMO); 95 recipients of an HLA-identical bone marrow
transplant (BMT) were randomized to receive intravenous 6-meth-
ylprednisolone (6MPred) 2 mg/kg per day for 5 days or 10 mg/kg
per day for 5 days as initial treatment of GvHD.4 The study showed
that a higher dose of 6MPred did not improve response rate or
survival, nor did it reduce transplant-related mortality (TRM). One
additional observation was that patients receiving 5 days of
6MPred 2 mg/kg, and who could taper their 6MPred dose on day
5 as per protocol, had a significantly lower TRM (23%)
compared with patients who could not taper their dose
(TRM 46%).4 This observation led us to identify responders as
patients who can follow the 6MPred tapering schedule.
We then designed a second study that would keep the low dose of
6MPred up front, and we could then test whether intensified second-line
treatment would reduce TRM. In this trial, all patients received 2 mg/kg
per day for 5 days at diagnosis of acute GvHD (grades I-IV); responders
were followed for events and survival, whereas nonresponders
were randomized for second-line 6MPred treatment with or
without anti–thymocyte globulin (ATG). We are now reporting the
outcome of 211 patients who entered this multicenter trial.
Patients, materials, and methods
Study design
This is a prospective multicenter trial of the Gruppo Italiano Trapianti di
Midollo Osseo (GITMO). Approval for these studies was obtained from the
ethics committee of the participating transplant centers. Informed consent
was provided according to the Declaration of Helsinki, approved by the
ethics committee, and signed by the patients.
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First-line therapy
Eligibility requirements were as follows: patients with acute GvHD grades I
to IV, undergoing unmanipulated HLA-identical sibling or MUD HSCT,
aged 1 to 60 years, any diagnosis, receiving GvHD prophylaxis with
cyclosporine (CsA, 1-3 mg/kg per day) or CsA  methotrexate (MTX),
with therapeutic plasma levels of CsA (200-400 ng/mL). Patients diagnosed
with aGvHD were treated, within 48 hours, with 6MPred at the dose of
2 mg/kg per day for 5 consecutive days (Figure 1). On day 5, patients
showing initial improvement of acute GvHD were supposed to have their
6MPred reduced to 1.5 mg/kg per day from day 6 to day  10 and to
1 mg/kg from day  11 to day  16. Failure to comply with the reduction
of the dose of 6MPred on day 5 was taken as evidence of nonresponse,
and patients were thus eligible for second-line therapy. Patients with acute
GvHD progressing within day 5 were also eligible for randomization
(Figure 1).
Response to first-line therapy
A surrogate criterion was used for GvHD response on day 5, that is, the
ability to reduce the GMPred dose as per protocol. Responders were
patients tapering their steroid dose, whereas failure to taper the dose was
taken as evidence of nonresponse.
Randomization to second-line therapy
Exclusion criteria for randomization were as follows: patients at the end
stage of disease; patients undergoing T-cell depletion or CD34 selection as
GvHD prophylaxis; patients who experienced an interval between GvHD
diagnosis and randomization of more than 7 days; patients responding on
day 5 to 6MPred 2 mg/kg; and patients receiving other experimental
drugs for GvHD treatment. Patients were stratified at randomization for age
( or  20 years), disease status (first remission or CP/more advanced),
and donor type (unrelated donors [UDs] or HLA-identical siblings [IDSs]).
Response to second-line therapy
We classified patients according to the response of GvHD. Complete
response was defined as complete resolution of all signs of GvHD; partial
response, reduction of GvHD to a less severe grading (ie, from grade III to
grade II), but still evidence of GvHD; stable GvHD, no change; and worse,
progression of GvHD to a more severe grading.
Second-line therapy
The regimen for group A was as follows: 6MPred 5 mg/kg per day (day 6 to
day 10; Figure 1), then 2.5 mg/kg from day 16 to day 20, then 1.5 mg/kg
from day 21 to day 30, and then 1 mg/kg from day 31 to day 35. The
regimen for group B was as follows: 6MPred 5 mg/kg with the addition of
rabbit anti–thymocyte globulin (ATG, thymoglobulin; Genzyme, Cam-
bridge, MA), 1.25 mg/kg on days 6, 8, 10, 12, and 14 (total dose, 7.25
mg/kg). ATG was given as a slow (12-18 hours) intravenous infusion, with
premedication with antihistamines. CsA was continued in order to maintain
therapeutic plasma levels. The tapering of 6MPred in group B was the same
as in group A. The design of second-line therapy, with an increase of
6Mpred from 2 mg/kg to 5 mg/kg, was justified by the fact that patients
could not be offered the same dose of 6Mpred that they had already failed.
Supportive care
All patients received antifungal and antibacterial prophylaxis and were
monitored for cytomegalovirus (CMV) as per institutional protocols. This
included, in all centers, preemptive treatment of CMV, based on CMV
antigenemia or CMV polymerase chain reaction (PCR), and antifungal
prophylaxis with fluconazole from day  7 to day  70. Early systemic
antifungal treatment based on Aspergillus antigenemia was used in most but
not all centers.
Statistical analysis
The NCSS package (NCSS, Keysville, UT) was used for chi-square tables,
actuarial survival, cumulative incidence (CI) rates, Student t test, and
Mann-Whitney test.
Results
First-line therapy
Two-hundred and eleven patients were registered as having acute
GvHD grade I and were given first-line treatment of 2 mg/kg per
day of 6MPred. On day 5, 150 patients (71%) had their dose of
6MPred tapered by 50% as per protocol and were considered
responders, whereas 61 patients (29%) were considered nonre-
sponders and were eligible for second-line therapy. We tested for
differences at the time of registration between these 2 groups
(Table 1). Nonresponders had higher grades of GvHD (P  .008)
and a trend for more advanced disease (P  .06). The proportion of
Figure 1. Trial design: all patients with a diagnosis of acute graft-versus-host
disease (GvHD) are treated with 6MPred 2 mg/kg per day from day 1 to day 5.
Responders have 6MPred tapered to 1.5 mg/kg from day 6 to day 10 and to 1 mg/kg
from day 11 to day 15. Nonresponders are randomized to (A) 6MPred 5 mg/kg from
day 6 to day 15, or (B) 6MPred 5 mg/kg from day 6 to day 15, and rabbit
anti–thymocyte globulin (ATG, thymoglobulin) 1.25 mg/kg on days 6, 8, 10, 12, and 14.
Table 1. Clinical characteristics of patients responding or not
responding to first-line treatment (univariate analysis)
Characteristic Responders Nonresponders P
Donor type, no.
HLA-identical sibling 80 30 —
Unrelated 70 31 .5
Median donor age, y (range) 36 (2-73) 42 (7-66) .1
Female donor/male recipient, no. (%) 39 (26) 10 (16) .1
Median recipient age, y (range) 32 (6-66) 34 (2-64) .2
Disease
Early disease, no. (%) 73 (49) 21 (35) .06
Conditioning with TBI, no. (%) 96 (64) 39 (66) .2
No. of cells infused, 108/kg (range) 4.6 (0.7-12.2) 4.6 (6.0-17) .1
GvHD prophylaxis CsA MTX, no. (%) 146 (98) 59 (97) .8
Grade of GvHD at registration, no.
I 91 24 —
II 49 27 —
III to IV 10 10 .008
Interval from Tx to GvHD, d (range) 16 (7-42) 17 (8-63) .1
Alive, no. (%) 84 (56) 22 (36) .02
Follow-up surviving patients, no.
(range) 1176 (129-1930) 1134 (37-1969) .8
Follow-up deceased patients, no.
(range) 203 (9-1809) 101 (15-1056) .3
Transplant-related deaths, no. (%) 40 (27) 30 (49) .001
Leukemia-related deaths, no. (%) 26 (17) 9 (15) .4
For responders, n  150 (71%); for nonresponders, n  61 (29%).
Tx indicates transplantation; —, not applicable.
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responders in patients with GvHD grades I, II, and III was 76%,
56%, and 52%, respectively (P  .01). There was no effect on day
5 response for any of the following: age, donor type, female
donor/male recipient, use of radiation, or number of cells infused.
The outcome of the 2 groups is outlined in Table 1. Of the
responders versus the nonresponders, respectively, 56% versus
36% of patients are alive, 27% versus 49% died of transplant-
related complications, and 17% versus 15% died of leukemia-
related events. The CI of TRM for responders and nonresponders
is, respectively, 27% and 49% (P  .009) (Figure 2A), with an
actuarial 5-year survival of 53% and 35% (P  .009) (Figure 2B).
The CI of TRM for patients with GvHD grade II on day 0 for
responders versus nonresponders, is 25% versus 53%, respectively
(P  .001). Causes of death in responders and nonresponders were
as follows: acute GvHD, 9 and 14, respectively; chronic GvHD, 10
and 4, respectively; infections, 11 and 6, respectively; other
transplant-related, 10 and 6, respectively; and leukemia, 26 and 9,
respectively. Therefore GvHD (acute  chronic) was the cause of
death in 19 (13%) of 150 responders and in 18 (30%) of 61 day5
nonresponders. The CI of TRM for patients with GvHD grades I, II,
and III is 28%, 36%, and 55%, respectively (P  .05); relapse-
related death, 20%, 14%, and 5%, respectively (P  .1); and
survival, 50%, 47%, and 36%, respectively (P  .1).
In multivariate COX analysis, predictors of TRM for the entire
patient population (n 211) were as follows: age older than
median ( 33 years) (RR, 2.27; P  .003); acute GvHD at
first-line treatment grade II (RR, 2.0; P  .01); lack of response
on day5 (RR, 1.76; P  .02); advanced disease phase (RR, 1.87;
P  .01); and transplant from an unrelated donor (RR, 1.64;
P  .05). Patients with no, one, or more than one unfavorable
predictor on day5 were scored as low risk (n 30), intermediate
risk (n 95), and high risk (n 86), respectively; the CI of TRM
in the 3 groups is 13%, 24%, and 50% (P  .001; Figure 3). By
using more than one variable, it may be possible to better predict
the outcome also of day 5 responders. Indeed, of the 150
responders, 30 (20%) were low risk, 88 (59%) were intermediate
risk, and 32 (21%) were high risk; conversely, of the 61 nonre-
sponders, 7 (11%) were intermediate risk.
Second-line treatment
Sixty-one nonresponders were randomized on day 5 to receive
6MPred 5 mg/kg per day for 10 days, alone (n 34) or in
combination with rabbit anti–thymocyte globulin (ATG, 6.25 mg/kg
in 10 days; n 27). The 2 groups were balanced for clinical and
GvHD characteristics (Table 2). One month after randomization,
26% had a complete response; 23%, partial response; 33%, stable
GvHD; 10%, worsened; and 8%, died (Figure 4A). There was no
significant difference in responses between non-ATG and ATG
Figure 2. Effect of response to first-line therapy on
outcome. (A) CI of TRM of day 5 responders (27%)
and day 5 nonresponders (49%) (P  .009). (B) Actu-
arial survival of responders (53%) and nonresponders
(35%) (P  .007).
Figure 3. Identifying patients in different risk groups after first-line therapy. CI
of TRM in 211 patients stratified as low, intermediate, and high risk on day 5 of
treatment for acute GvHD. See multivariate COX analysis in “First-line therapy.”
Table 2. Characteristics of patients randomized to
second-line therapy
Characteristic Non-ATG ATG P
Recipient sex, no. male/no. female 17/17 15/12 .6
Median recipient age, y (range) 33 (2-64) 36 (2-63) .4
Donor type, no.
HLA-identical sibling 16 14 —
Unrelated 18 13 .7
Diagnosis, no.
AML ALL 18 12 —
CML 12 7 —
LY/MM 1 4 —
Other 3 4 .3
Advanced phase 22 (67%) 16 (59%) .4
14 or fewer days of first-line treatment, no. 7 8 .4
Timing of GvHD, 14 d after transplantation 7 7 .4
GvHD grade at randomization, no.
I 7 4 —
II 19 16 —
III 8 7 .5
Skin GvHD day 5, no. 33* 26 .3
Liver GvHD day 5, no. 14 7 .2
Gut GvHD day 5, no. 17 14 .9
Response at day30, no. (%)
Resolution of GvHD 8 (24) 9 (33) —
Partial resolution 8 (24) 6 (22) —
Stable GvHD 13 (38) 5 (19) —
Worsened 4 (12) 2 (7) —
Dead 1 (3) 5 (19) —
Alive 13 (38) 9 (33) .9
Dead TRM 14 (41) 16 (59) .2
Dead relapse 7 (21) 2 (8) .1
For patients not given ATG, n  34; for patients given ATG, n  27.
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic leukemia;
CML, chronic myelogenous leukemia; LY, lymphoma; MM, multiple myeloma; —, not
applicable.
*Number of patients with skin, liver, or gut GvHD on day 5 (at the time of
randomization).
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patients, as outlined in Figure 4B. The actuarial survival of
non-ATG and ATG patients was 36% and 34%, respectively
(P  .63; Figure 5A), and the CI of TRM was 41% and 59%
(P  .17; Figure 5B). Causes of death in the non-ATG group were
as follows: acute GvHD (n 8), chronic GvHD (n 3), cerebral
hemorrhage (n 1), infections (n 1), multiorgan failure (MOF;
n  1), and relapse (n 7). In the ATG group, the causes of death
were as follows: acute GvHD (n 6), chronic GvHD (n 1),
Epstein-Barr virus (EBV) lymphoma (n 1), infections (n 4),
MOF (n 2), hemorrhagic cystitis (n 1), suicide (n 1), and
relapse (n 2). Infectious complications in the ATG group in-
cluded EBV (n 1), CMV (n 4), pneumonia (n 1), and sepsis
(n  1). The median time from transplantation to TRM was similar
in the non-ATG and the ATG groups (84 and 100 days, respec-
tively). Platelet counts were also followed in the non-ATG and the
ATG groups: median platelet counts at time of randomization were
77  109/L and 57 109/L, respectively; on day10, 76 109/L
and 63  109/L, respectively; on day 30, 49  109/L and
59  109/L, respectively; and on day 180, 115  109/L and
154 109/L, respectively. When patients were stratified for GvHD
severity at the time of randomization, TRM was 36% for GvHD
grade I (n 11), 43% for grade II (n  35), and 73% for grades III
to IV (n 15) (P  .09). TRM was 29% for patients without gut or
liver involvement (n 21), 54% for patients with either gut or
liver involvement (n 28), and 75% for patients with both gut and
liver GvHD (n 12) (P  .03). When only gut/liver GvHD
patients were considered, TRM was again higher in patients
receiving than those not receiving ATG (76% and 47%, respec-
tively; P  .06).
In multivariate COX analysis, predictors of TRM, for patients
receiving second-line treatment, were as follows: age older than 33
years (RR, 3.0; P  .01); the presence of gut or liver GvHD at time
of randomization (RR, 3.74; P  .003); the use of ATG (RR, 2.69;
P  .01); and advanced disease (RR, 2.27; P  .04).
Discussion
This study was designed primarily to test whether intensified
second-line treatment of acute GvHD would reduce TRM; because
all patients were registered at diagnosis of acute GvHD and
received the same first-line therapy, 6MPred 2 mg/kg per day, a
second objective was to follow patients responding to steroids on
day5. The results of the study can be summarized as follows: (a)
5-day treatment of GvHD is useful to identify patients with
different risk of TRM; (b) second-line therapy with a combination
of 6MPred  ATG does not improve patient outcome, compared
with 6MPred alone.
As to first-line therapy, the major predictor of response was
grading of acute GvHD at the time of first-line therapy; there were
more patients with GvHD grade I in responders, and, conversely,
responses were significantly lower in patients with GvHD grade II
or grades III to IV. It is interesting that donor type and age were not
major predictors of response on day5.
The outcome of responders was significantly superior compared
with nonresponders in terms of TRM and survival, and this
confirms our previous work and other studies.4,5 This was true for
the entire group of patients registered and also when excluding
GvHD grade I. Of interest, TRM of day 5 responders and
nonresponders (23% and 43%, respectively) in our previous study
was the same as in the current study (27% and 49%, respectively),
despite the fact that half of the donors are currently unrelated. Still,
we are faced with TRM also in responders, and we wanted to test
for other predictors; as expected, older age, advanced disease,
unrelated donor, and higher GvHD grade were all independent
predictors of TRM together with day 5 response. We could,
therefore, build a scoring system based on these variables that
identified on day5 patients with low (13%), intermediate (24%),
or high (50%) risk of TRM. This may be of some clinical relevance,
especially for low-risk patients who could be eligible for trials of
rapid tapering of immunosuppressive therapy; it could also be used
in patients who seem to do well initially but then have flares of
GvHD or additional complications. Indeed, 59% of responders
were classified as intermediate-risk patients and 21% as high-risk
patients. Thus, response on day 5 is important, but other clinical
variables need to be taken into account for a more accurate
prediction of mortality.
Second-line treatment was given to day5 nonresponders, in a
randomized fashion, to test whether the combination of 6MPred
and ATG would reduce TRM compared with 6MPred alone.
After 30 days from randomization, half the patients had a
complete or partial response, one third had stable disease, and
20% had either progressed or died. There were no major
Figure 4. Response rates to second-line therapy. (A) Response rates evaluated at
30 days of second-line treatment for acute GvHD in all 61 eligible patients. CR
indicates complete responses; PR, partial responses; stable, stable disease; and
worse, patients with progressive GvHD. (B) Responses in 61 patients according to
randomization arm: no ATG (gray bars) or ATG (black bars). There is no significant
difference in responses (48% vs 55% CR PR; P  .3) in the 2 treatment groups, or
in patients who worsened or died (15% vs 26%, P  .2).
Figure 5. The effect of ATG given as second-line
therapy on outcome. (A) CI of TRM in 61 patients
according to randomization arm: no ATG or ATG. (B)
Actuarial survival in 61 patients according to randomiza-
tion arm: no ATG or ATG.
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differences in terms of response when comparing patients given
6MPred alone or the combination of 6MPred and ATG. The
latter had borderline higher TRM; actually, in multivariate
analysis, with patient age, disease phase, visceral GvHD, and
donor type, the use of ATG significantly increased the risk of
TRM (RR  2.69) compared with patients receiving steroids
alone. Again, in keeping with other studies,6 we come to the
same conclusion: intensive systemic immunosuppression is not
beneficial—and possibly detrimental—in patients with acute
GvHD. This is true for ATG,6 CD5 immunotoxins,7 T-cell
monoclonal antibodies,8-17 antibodies against TNF,18-20 and
high-dose steroids.4 All of these agents are capable of inducing
remission, but nonrelapse mortality remains high, despite con-
trol of GvHD, primarily due to intervening infections or related
complications.2,21-23 Prophylaxis and treatment of infectious
complications are rather aggressive in transplant centers, and it
would seem unlikely that these policies may be further imple-
mented and reduce infectious problems in these severely
immunocompromised patients.
Where do we go from here? One question that needs to be
answered is when do we start treatment of acute GvHD? Should
we treat GvHD grade I or should we wait until GvHD grade II
develops? Most studies call for GvHD grade II to initiate
treatment, and many (but not all) centers treat only GvHD grade
II.24 It should not be difficult to randomize patients with GvHD
grade I to receive 6MPred 2 mg/kg per day for 5 days or be left
untreated until spontaneous response or progression occurs.
This would tell us if early is better than late treatment. A second
question relates to tapering steroids: it is unclear whether
different tapering schedules influence survival and one could
ask if a rapid tapering would spare a number of side effects.
Finally, we still need to test whether GvHD can be preempted;
this implies identifying high-risk patients early after transplanta-
tion25 and then treating only these patients.
In conclusion, this study confirms that second-line therapy
with a combination of steroids and ATG does not improve
patient outcome compared with steroids alone. It also shows that
patients could be assigned to different risk groups on day 5
from diagnosis of GvHD and could be eligible for different
treatment strategies.
Appendix
Participating members of the Gruppo Italiano Midollo Osseo (GITMO)
included A. Bacigalupo, Ospedale San Marino, Genoa; G. Milone, Osped-
ale Ferrarotto, Catania; G. Masera, Clinica Pediatrica, Monza; R. Scime`,
Ospedale Cervello, Palermo; G. Dini, Medicina IV, Gaslini; A. Bosi,
Ospedale Careggi, Florence; I. Majolino, Ospedale San Camillo, Rome; G.
Leone, Universita` Cattolica, Rome; E. Madon, Clinica Pediatrica, Turin; A.
Gallamini, Cuneo; W. Arcese, Universita` Tor Vergata, Rome; and B. Rotoli,
Ospedale Cardarelli, Naples.
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